Hypothalamic syndrome (HS) is a rare disorder caused by disease-related and/or treatment-related injury to the hypothalamus, most commonly associated with rare, non-cancerous parasellar masses, such as craniopharyngiomas, germ cell tumours, gliomas, cysts of Rathke’s pouch and Langerhans cell histiocytosis, as well as with genetic neurodevelopmental syndromes, such as Prader–Willi syndrome and septo-optic dysplasia. HS is characterized by intractable weight gain associated with severe morbid obesity, multiple endocrine abnormalities and memory impairment, attention deficit and reduced impulse control as well as increased risk of cardiovascular and metabolic disorders. Currently, there is no cure for this condition but treatments for general obesity are often used in patients with HS, including surgery, medication and counselling. However, these are mostly ineffective and no medications that are specifically approved for the treatment of HS are available. Specific challenges in HS are because the syndrome represents an adverse effect of different diseases, and that diagnostic criteria, aetiology, pathogenesis and management of HS are not completely defined.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Zacharia, B. E. et al. Incidence, treatment and survival of patients with craniopharyngioma in the Surveillance, Epidemiology and End Results Program. Neurooncology 14, 1070–1078 (2012).
Muller, H. L., Merchant, T. E., Warmuth-Metz, M., Martinez-Barbera, J. P. & Puget, S. Craniopharyngioma. Nat. Rev. Dis. Prim. 5, 75 (2019).
van Iersel, L. et al. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review. Endocr. Rev. 40, 193–235 (2019). A comprehensive review of hypothalamic dysfunction and all reported interventions aiming to improve hypothalamic obesity, and a proposed treatment algorithm.
Muller, H. L. Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 23, 81–89 (2016).
Muller, H. L. Consequences of craniopharyngioma surgery in children. J. Clin. Endocrinol. Metab. 96, 1981–1991 (2011).
Muller, H. L. The diagnosis and treatment of craniopharyngioma. Neuroendocrinology 110, 753–766 (2020).
Sterkenburg, A. S. et al. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neurooncology 17, 1029–1038 (2015). A a 20-year follow-up analysis of 485 patients with childhood-onset craniopharyngioma that showed impaired overall survival in patients with hypothalamic involvement. Relapse and progression rates were similar with regard to different degrees of resection (gross total resection versus incomplete resection).
Otte, A. & Müller, H. L. Childhood-onset craniopharyngioma. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/clinem/dgab397 (2021). A recent comprehensive review of craniopharyngioma.
Muller, H. L., Merchant, T. E., Puget, S. & Martinez-Barbera, J. P. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat. Rev. Endocrinol. 13, 299–312 (2017).
Harz, K. J., Muller, H. L., Waldeck, E., Pudel, V. & Roth, C. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J. Clin. Endocrinol. Metab. 88, 5227–5231 (2003).
Prader, A. Ein Syndrom von adipositas, kleinwuchs, kryptorchismus und oligophrenie nach myatonieartigem zustand im neugeborenenalter [German]. Schweiz. Med. Wochenschr. 86, 1260–1261 (1956).
Cemeroglu, A. P., Coulas, T. & Kleis, L. Spectrum of clinical presentations and endocrinological findings of patients with septo-optic dysplasia: a retrospective study. J. Pediatr. Endocrinol. Metab. 28, 1057–1063 (2015).
Tauber, M. & Hoybye, C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol. 9, 235–246 (2021). A recent comprehensive review of hypothalamic dysfunction in patients with PWS.
Muller, H. L. Management of endocrine disease: childhood-onset craniopharyngioma: state of the art of care in 2018. Eur. J. Endocrinol. 180, R159–R174 (2019).
Muller, H. L. Hypothalamic involvement in craniopharyngioma – implications for surgical, radiooncological, and molecularly targeted treatment strategies. Pediatr. blood cancer 65, e26936 (2018).
Parkinson, W. L. & Weingarten, H. P. Dissociative analysis of ventromedial hypothalamic obesity syndrome. Am. J. Physiol. 259, R829–R835 (1990).
Bunin, G. R. et al. The descriptive epidemiology of craniopharyngioma. J. Neurosurg. 89, 547–551 (1998).
Santagata, S., Kleinschmidt-DeMasters, B. K., Komori, T., Müller, H. L., Pietsch, T. in Central Nervous System Tumours. WHO Classification of Tumours 5th edn Vol. 6 (WHO Classification of Tumours Editorial Board) 393–396 (IARC, 2021).
Hafez, M. A., ElMekkawy, S., AbdelBadie, H., Mohy, M. & Omar, M. Pediatric craniopharyngioma – rationale for multimodal management: the Egyptian experience. J. Pediatr. Endocrinol. Metab. 19 (Suppl. 1), 371–380 (2006).
Zhang, Y. Q., Wang, C. C. & Ma, Z. Y. Pediatric craniopharyngiomas: clinicomorphological study of 189 cases. Pediatr. Neurosurg. 36, 80–84 (2002).
Adeloye, A., Nottidge, V. A. & Udi, J. Craniopharyngioma in Nigerian children. Childs Nerv. Syst. 4, 128–134 (1988).
Ersahin, Y., Yurtseven, T., Ozgiray, E. & Mutluer, S. Craniopharyngiomas in children: Turkey experience. Childs Nerv. Syst. 21, 766–772 (2005).
Amayiri, N. et al. Review of management and morbidity of pediatric craniopharyngioma patients in a low-middle-income country: a 12-year experience. Childs Nerv. Syst. 33, 941–950 (2017).
Chaudhry, N. S., Raber, M. R., Cote, D. J. & Laws, E. R. Jr. Spontaneous pituitary adenoma occurring after resection of a Rathke’s cleft cyst. J. Clin. Neurosci. 33, 247–251 (2016).
Suh, Y. L. et al. Tumors of the central nervous system in Korea: a multicenter study of 3221 cases. J. Neurooncol. 56, 251–259 (2002).
Gittleman, H. et al. Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. J. Neurooncol. 143, 251–260 (2019).
Kakkar, A. et al. Erratum to: Intracranial germ cell tumors: a multi-institutional experience from three tertiary care centers in India. Childs Nerv. Syst. 32, 2181 (2016).
Keene, D. et al. Epidemiological survey of central nervous system germ cell tumors in Canadian children. J. Neurooncol. 82, 289–295 (2007).
Lee, S. H. et al. Nationwide population-based incidence and survival rates of malignant central nervous system germ cell tumors in Korea, 2005-2012. Cancer Res. Treat. 49, 494–501 (2017).
Kuratsu, J., Takeshima, H. & Ushio, Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int. J. Clin. Oncol. 6, 183–191 (2001).
Peckham-Gregory, E. C. et al. Evaluation of racial disparities in pediatric optic pathway glioma incidence: results from the Surveillance, Epidemiology, and End Results Program, 2000-2014. Cancer Epidemiol. 54, 90–94 (2018).
Avery, R. A. et al. Quantitative MRI criteria for optic pathway enlargement in neurofibromatosis type 1. Neurology 86, 2264–2270 (2016).
Guyot-Goubin, A. et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr. Blood Cancer 51, 71–75 (2008).
Salotti, J. A. et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch. Dis. Child. 94, 376–380 (2009).
Horibe, K. et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology. Int. J. Hematol. 98, 74–88 (2013).
Stalemark, H. et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr. Blood Cancer 51, 76–81 (2008).
Alston, R. D. et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr. Blood Cancer 48, 555–560 (2007).
Makras, P., Stathi, D., Yavropoulou, M., Tsoli, M. & Kaltsas, G. The annual incidence of Langerhans cell histiocytosis among adults living in Greece. Pediatr. Blood Cancer 67, e28422 (2020).
Passone, C. G. B. et al. Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis. BMJ Paediatr. Open 4, e000630 (2020).
Whittington, J. E., Butler, J. V. & Holland, A. J. Changing rates of genetic subtypes of Prader-Willi syndrome in the UK. Eur. J. Hum. Genet. 15, 127–130 (2007).
Bar, C. et al. Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome. Orphanet J. Rare Dis. 12, 118 (2017).
Smith, A. et al. Birth prevalence of Prader-Willi syndrome in Australia. Arch. Dis. Child. 88, 263–264 (2003).
Vogels, A. et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur. J. Hum. Genet. 12, 238–240 (2004).
Lionti, T., Reid, S. M., White, S. M. & Rowell, M. M. A population-based profile of 160 Australians with Prader-Willi syndrome: trends in diagnosis, birth prevalence and birth characteristics. Am. J. Med. Genet. A 167A, 371–378 (2015).
Patel, L., McNally, R. J., Harrison, E., Lloyd, I. C. & Clayton, P. E. Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. J. Pediatr. 148, 85–88 (2006).
Khaper, T. et al. Increasing incidence of optic nerve hypoplasia/septo-optic dysplasia spectrum: Geographic clustering in Northern Canada. Paediatr. Child. Health 22, 445–453 (2017).
Bedont, J. L., Newman, E. A. & Blackshaw, S. Patterning, specification, and differentiation in the developing hypothalamus. Wiley Interdiscip. Rev. Dev. Biol. 4, 445–468 (2015).
Bereket, A. et al. Hypothalamic obesity in children. Obes. Rev. 13, 780–798 (2012).
Swaab, D. F. Neuropeptides in hypothalamic neuronal disorders. Int. Rev. Cytol. 240, 305–375 (2004).
Park, A. J. & Bloom, S. R. Neuroendocrine control of food intake. Curr. Opin. Gastroenterol. 21, 228–233 (2005).
Ferguson, A. V., Latchford, K. J. & Samson, W. K. The paraventricular nucleus of the hypothalamus–a potential target for integrative treatment of autonomic dysfunction. Expert Opin. Ther. Targets 12, 717–727 (2008).
Yang, T. et al. Social control of hypothalamus-mediated male aggression. Neuron 95, 955–970 e954 (2017).
Hu, R. K. et al. An amygdala-to-hypothalamus circuit for social reward. Nat. Neurosci. 24, 831–842 (2021).
Boekhoff, S., Bogusz, A., Sterkenburg, A. S., Eveslage, M. & Muller, H. L. Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo). Eur. J. Endocrinol. 179, 331–341 (2018).
Roth, C. L., Gebhardt, U. & Muller, H. L. Appetite-regulating hormone changes in patients with craniopharyngioma. Obesity 19, 36–42 (2011). An important paper on the appetite-regulating hormones.
McCormack, S. E., Blevins, J. E. & Lawson, E. A. Metabolic effects of oxytocin. Endocr. Rev. https://doi.org/10.1210/endrev/bnz012 (2020). A comprehensive review of oxytocin.
Plessow, F. et al. Effects of intranasal oxytocin on the blood oxygenation level-dependent signal in food motivation and cognitive control pathways in overweight and obese men. Neuropsychopharmacology 43, 638–645 (2018).
Plessow, F., Marengi, D. A., Perry, S. K. & Lawson, E. A. Oxytocin administration increases proactive control in men with overweight or obesity: a randomized, double-blind, placebo-controlled crossover study. Obesity 29, 56–61 (2021).
Bomer, I. et al. Comparison of energy expenditure, body composition, metabolic disorders, and energy intake between obese children with a history of craniopharyngioma and children with multifactorial obesity. J. Pediatr. Endocrinol. Metab. 28, 1305–1312 (2015).
Bekx, M. T., Carrel, A. L., Shriver, T. C., Li, Z. & Allen, D. B. Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi syndrome. J. Pediatr. 143, 372–376 (2003).
Roth, C. L. et al. Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr. Res. 61, 496–501 (2007).
Muller, H. L. Increased daytime sleepiness in patients with childhood craniopharyngioma and hypothalamic tumor involvement: review of the literature and perspectives. Int. J. Endocrinol. 2010, 519607 (2010).
Muller, H. L. et al. Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes Control 17, 583–589 (2006).
Muller, H. L., Handwerker, G., Wollny, B., Faldum, A. & Sorensen, N. Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J. Clin. Endocrinol. Metab. 87, 3993–3996 (2002).
Berthoud, H. R. & Jeanrenaud, B. Acute hyperinsulinemia and its reversal by vagotomy after lesions of the ventromedial hypothalamus in anesthetized rats. Endocrinology 105, 146–151 (1979).
Thaler, J. P. & Schwartz, M. W. Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 151, 4109–4115 (2010).
Bhusal, A., Rahman, M. H. & Suk, K. Hypothalamic inflammation in metabolic disorders and aging. Cell. Mol. Life Sci. 79, 32 (2021).
Moller, M. Vasopressin and oxytocin beyond the pituitary in the human brain. Handb. Clin. Neurol. 180, 7–24 (2021).
Pascual, J. M. et al. Craniopharyngiomas primarily involving the hypothalamus: a model of neurosurgical lesions to elucidate the neurobiological basis of psychiatric disorders. World Neurosurg. 120, e1245–e1278 (2018).
Bauer, H. G. Endocrine and other clinical manifestations of hypothalamic disease; a survey of 60 cases, with autopsies. J. Clin. Endocrinol. Metab. 14, 13–31 (1954).
Zada, G., Kintz, N., Pulido, M. & Amezcua, L. Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: a systematic literature review. PLoS ONE 8, e76562 (2013).
Ozyurt, J., Muller, H. L. & Thiel, C. M. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J. Neurooncol. 125, 9–21 (2015). A comprehensive review of the neuropsychological sequelae in childhood-onset craniopharyngioma.
Vann, S. D. Re-evaluating the role of the mammillary bodies in memory. Neuropsychologia 48, 2316–2327 (2010).
Erfurth, E. M. Diagnosis, background, and treatment of hypothalamic damage in craniopharyngioma. Neuroendocrinology 110, 767–779 (2020).
Parkin, A. J. & Hunkin, N. M. Impaired temporal context memory on anterograde but not retrograde tests in the absence of frontal pathology. Cortex 29, 267–280 (1993).
Dekkers, O. M. et al. Quality of life in treated adult craniopharyngioma patients. Eur. J. Endocrinol. 154, 483–489 (2006).
Fournier-Goodnight, A. S. et al. Neurocognitive functioning in pediatric craniopharyngioma: performance before treatment with proton therapy. J. Neurooncol. 134, 97–105 (2017).
Whittington, J. & Holland, A. Cognition in people with Prader-Willi syndrome: insights into genetic influences on cognitive and social development. Neurosci. Biobehav. Rev. 72, 153–167 (2017).
Ronson, A. Psychiatric disorders in oncology: recent therapeutic advances and new conceptual frameworks. Curr. Opin. Oncol. 16, 318–323 (2004).
Leibenluft, E. Pediatric irritability: a systems neuroscience approach. Trends Cogn. Sci. 21, 277–289 (2017).
Wong, T. Y. et al. Neural networks of aggression: ALE meta-analyses on trait and elicited aggression. Brain Struct. Funct. 224, 133–148 (2019).
Ozyurt, J., Mehren, A., Boekhoff, S., Muller, H. L. & Thiel, C. M. Social cognition in patients with hypothalamic-pituitary tumors. Front. Oncol. 10, 1014 (2020). A study that demonstrates the effects of acquired hypothalamic damage on social cognition.
Sternson, S. M. Hypothalamic survival circuits: blueprints for purposive behaviors. Neuron 77, 810–824 (2013).
Averbeck, B. B. & Murray, E. A. Hypothalamic interactions with large-scale neural circuits underlying reinforcement learning and motivated behavior. Trends Neurosci. 43, 681–694 (2020).
Mehren, A. et al. Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma. J. Neurooncol. 140, 27–35 (2018).
Le Heron, C., Apps, M. A. J. & Husain, M. The anatomy of apathy: a neurocognitive framework for amotivated behaviour. Neuropsychologia 118, 54–67 (2018).
Neumann, I. D. & Landgraf, R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci. 35, 649–659 (2012).
Kim, J. H. & Choi, J. H. Pathophysiology and clinical characteristics of hypothalamic obesity in children and adolescents. Ann. Pediatr. Endocrinol. Metab. 18, 161–167 (2013).
Tena-Suck, M. L. et al. Intracerebral injection of oil cyst content of human craniopharyngioma (oil machinery fluid) as a toxic model in the rat brain. Acta Histochemica 116, 448–456 (2014).
Ghosh, M. et al. Effects of craniopharyngioma cyst fluid on neurons and glial cells cultured from rat brain hypothalamus. J. Chem. Neuroanat. 94, 93–101 (2018).
Romijn, J. A. The chronic syndromes after previous treatment of pituitary tumours. Nat. Rev. Endocrinol. 12, 547–556 (2016).
Goschzik, T. et al. Genomic alterations of adamantinomatous and papillary craniopharyngioma. J. Neuropathol. Exp. Neurol. 76, 126–134 (2017).
Barry, S. & Korbonits, M. Update on the genetics of pituitary tumors. Endocrinol. Metab. Clin. North. Am. 49, 433–452 (2020).
Martinez-Barbera, J. P. & Buslei, R. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models. J. Pediatr. Endocrinol. Metab. 28, 7–17 (2015).
Gaston-Massuet, C. et al. Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. Proc. Natl Acad. Sci. USA 108, 11482–11487 (2011).
Martinez-Barbera, J. P. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma. Neuropathol. Appl. Neurobiol. 41, 721–732 (2015).
Gonzalez-Meljem, J. M. et al. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nat. Commun. 8, 1819 (2017).
Gonzalez-Meljem, J. M. & Martinez-Barbera, J. P. Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis. Cell. Mol. Life Sci. 78, 4521–4544 (2021).
De Souza, C. T. et al. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 146, 4192–4199 (2005).
Zhang, X. et al. Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell 135, 61–73 (2008).
Webb, E. A. & Dattani, M. T. Septo-optic dysplasia. Eur. J. Hum. Genet. 18, 393–397 (2010).
Bosch, I. A. L., Katugampola, H. & Dattani, M. T. Congenital hypopituitarism during the neonatal period: epidemiology, pathogenesis, therapeutic options, and outcome. Front. Pediatr. 8, 600962 (2020).
Inoue, T., Nakamura, S. & Osumi, N. Fate mapping of the mouse prosencephalic neural plate. Dev. Biol. 219, 373–383 (2000).
Dattani, M. T. et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat. Genet. 19, 125–133 (1998).
Kelberman, D. et al. SOX2 plays a critical role in the pituitary, forebrain, and eye during human embryonic development. J. Clin. Endocrinol. Metab. 93, 1865–1873 (2008).
Jayakody, S. A. et al. SOX2 regulates the hypothalamic-pituitary axis at multiple levels. J. Clin. Invest. 122, 3635–3646 (2012).
Sarmah, S. et al. Embryonic ethanol exposure alters expression of sox2 and other early transcripts in zebrafish, producing gastrulation defects. Sci. Rep. 10, 3951 (2020).
Ahlgren, S. C., Thakur, V. & Bronner-Fraser, M. Sonic hedgehog rescues cranial neural crest from cell death induced by ethanol exposure. Proc. Natl Acad. Sci. USA 99, 10476–10481 (2002).
Kahn, B. M. et al. Prenatal ethanol exposure in mice phenocopies Cdon mutation by impeding Shh function in the etiology of optic nerve hypoplasia. Dis. Model. Mech. 10, 29–37 (2017).
Butler, M. G. & Duis, J. Chromosome 15 imprinting disorders: genetic laboratory methodology and approaches. Front. Pediatr. 8, 154 (2020).
Cheon, C. K. Genetics of Prader-Willi syndrome and Prader-Will-Like syndrome. Ann. Pediatr. Endocrinol. Metab. 21, 126–135 (2016).
Bieth, E. et al. Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi syndrome. Eur. J. Hum. Genet. 23, 252–255 (2015).
Sahoo, T. et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat. Genet. 40, 719–721 (2008).
Duker, A. L. et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur. J. Hum. Genet. 18, 1196–1201 (2010).
de Smith, A. J. et al. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum. Mol. Genet. 18, 3257–3265 (2009).
Polex-Wolf, J. et al. Hypothalamic loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome. J. Clin. Invest. 128, 960–969 (2018).
Kim, Y. et al. Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome. Nat. Med. 23, 213–222 (2017).
Bischof, J. M., Stewart, C. L. & Wevrick, R. Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader-Willi syndrome. Hum. Mol. Genet. 16, 2713–2719 (2007).
Andrieu, D. et al. Sensory defects in Necdin deficient mice result from a loss of sensory neurons correlated within an increase of developmental programmed cell death. BMC Dev. Biol. 6, 56 (2006).
Lukoshe, A. et al. Altered functional resting-state hypothalamic connectivity and abnormal pituitary morphology in children with Prader-Willi syndrome. J. Neurodev. Disord. 9, 12 (2017).
Bochukova, E. G. Transcriptomics of the Prader-Willi syndrome hypothalamus. Handb. Clin. Neurol. 181, 369–379 (2021).
Kummerfeld, D. M. et al. A comprehensive review of genetically engineered mouse models for Prader-Willi syndrome research. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22073613 (2021).
Correa-da-Silva, F., Fliers, E., Swaab, D. F. & Yi, C. X. Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome. J. Neuroendocrinol. https://doi.org/10.1111/jne.12994 (2021). A very well-written overview of important hypothalamic neuropeptides and circuits involved in hypothalamic dysfunction in PWS.
Bougneres, P., Pantalone, L., Linglart, A., Rothenbuhler, A. & Le Stunff, C. Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. J. Clin. Endocrinol. Metab. 93, 3971–3980 (2008).
Lazea, C., Sur, L. & Florea, M. ROHHAD (rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation) syndrome – what every pediatrician should know about the etiopathogenesis, diagnosis and treatment: a review. Int. J. Gen. Med. 14, 319–326 (2021).
Sanklecha, M., Sundaresan, S. & Udani, V. ROHHAD syndrome: the girl who forgets to breathe. Indian. Pediatr. 53, 343–344 (2016).
Giacomozzi, C. et al. Anti-hypothalamus and anti-pituitary auto-antibodies in ROHHAD syndrome: additional evidence supporting an autoimmune etiopathogenesis. Horm. Res. Paediatr. 92, 124–132 (2019).
Paz-Priel, I., Cooke, D. W. & Chen, A. R. Cyclophosphamide for rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome. J. Pediatrics 158, 337–339 (2011).
Jacobson, L. A. et al. Improved behavior and neuropsychological function in children with ROHHAD after high-dose cyclophosphamide. Pediatrics https://doi.org/10.1542/peds.2015-1080 (2016).
van Schaik, J. et al. The importance of specialized sleep investigations in children with a suprasellar tumor. Pituitary 23, 613–621 (2020).
Gunay-Aygun, M., Schwartz, S., Heeger, S., O’Riordan, M. A. & Cassidy, S. B. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 108, E92 (2001).
Harvengt, J. et al. ROHHAD(NET) syndrome: systematic review of the clinical timeline and recommendations for diagnosis and prognosis. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/clinem/dgaa247 (2020).
Muller, H. L. et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur. J. Endocrinol. 165, 17–24 (2011).
Puget, S. et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J. Neurosurg. 106, 3–12 (2007).
Elliott, R. E., Sands, S. A., Strom, R. G. & Wisoff, J. H. Craniopharyngioma clinical status scale: a standardized metric of preoperative function and posttreatment outcome. Neurosurg. Focus. 28, E2 (2010).
Perez, F. A. et al. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. Diabetes Obes. Metab. 23, 1532–1541 (2021).
Merchant, T. E. et al. Phase II trial of conformal radiation therapy for pediatric patients with craniopharyngioma and correlation of surgical factors and radiation dosimetry with change in cognitive function. J. Neurosurg. 104, 94–102 (2006).
Warmuth-Metz, M. Imaging and Diagnosis in Pediatric Brain Tumor Studies 44–50 (Springer, 2017).
Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803–820 (2016).
Hoffmann, A., Brentrup, A. & Muller, H. L. First report on spinal metastasis in childhood-onset craniopharyngioma. J. Neurooncol. 129, 193–194 (2016).
Muller, H. L. et al. Xanthogranuloma, Rathke’s cyst, and childhood craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations. J. Clin. Endocrinol. Metab. 97, 3935–3943 (2012).
Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A. & Muller, H. L. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur. J. Pediatrics 177, 125–132 (2018).
Yamada, K., Matsuzawa, H., Uchiyama, M., Kwee, I. L. & Nakada, T. Brain developmental abnormalities in Prader-Willi syndrome detected by diffusion tensor imaging. Pediatrics 118, e442–e448 (2006).
Holsen, L. M. et al. Neural mechanisms underlying hyperphagia in Prader-Willi syndrome. Obesity 14, 1028–1037 (2006).
Kang, J. et al. Predicting the location of the preoptic and anterior hypothalamic region by visualizing the thermoregulatory center on fMRI in craniopharyngioma using cold and warm stimuli. Aging 13, 10087–10098 (2021).
Muller, H. L. Management of hypothalamic obesity. Endocrinol. Metab. Clin. North Am. 49, 533–552 (2020).
Muller, H. L. et al. Prognosis and sequela in patients with childhood craniopharyngioma – results of HIT-ENDO and update on KRANIOPHARYNGEOM 2000. Klinische Padiat. 216, 343–348 (2004).
Muller, H. L. et al. Obesity after childhood craniopharyngioma – German multicenter study on pre-operative risk factors and quality of life. Klinische Padiat. 213, 244–249 (2001).
Hoffmann, A., Gebhardt, U., Sterkenburg, A. S., Warmuth-Metz, M. & Muller, H. L. Diencephalic syndrome in childhood craniopharyngioma – results of German multicenter studies on 485 long-term survivors of childhood craniopharyngioma. J. Clin. Endocrinol. Metab. 99, 3972–3977 (2014).
Gnekow, A. K. et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neurooncology 14, 1265–1284 (2012).
Yody, B. B. et al. Applied behavior management and acquired brain injury: approaches and assessment. J. Head. Trauma Rehabil. 15, 1041–1060 (2000).
Holmes, E. A. et al. The Lancet Psychiatry Commission on psychological treatments research in tomorrow’s science. Lancet Psychiatry 5, 237–286 (2018).
Hocking, M. C. et al. Social competence in pediatric brain tumor survivors: application of a model from social neuroscience and developmental psychology. Pediatr. Blood Cancer 62, 375–384 (2015).
Denzer, C. et al. Treatment of hypothalamic obesity with dextroamphetamine: a case series. Obes. Facts 12, 91–102 (2019).
Elfers, C. T. & Roth, C. L. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Front. Endocrinol. 2, 78 (2011).
Dykens, E. M., Maxwell, M. A., Pantino, E., Kossler, R. & Roof, E. Assessment of hyperphagia in Prader-Willi syndrome. Obesity 15, 1816–1826 (2007).
Schwartz, L. et al. Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium. J. Neurodev. Disord. 13, 25 (2021).
Dykens, E. M. et al. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome. JCI Insight https://doi.org/10.1172/jci.insight.98333 (2018).
Lomenick, J. P., Buchowski, M. S. & Shoemaker, A. H. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity 24, 1222–1225 (2016).
Zoicas, F., Droste, M., Mayr, B., Buchfelder, M. & Schofl, C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur. J. Endocrinol. 168, 699–706 (2013).
Simmons, J. H., Shoemaker, A. H. & Roth, C. L. Treatment with glucagon-like peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor. Horm. Res. Paediatr. 78, 54–58 (2012).
Thondam, S. K. et al. A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin. Endocrinol. 77, 635–637 (2012).
Castro-Dufourny, I., Carrasco, R. & Pascual, J. M. Hypothalamic obesity after craniopharyngioma surgery: treatment with a long acting glucagon like peptide 1 derivated. Endocrinol. Diabetes Nutr. 64, 182–184 (2017).
van Santen, S. S. et al. Bariatric surgery for hypothalamic obesity in craniopharyngioma patients: a retrospective, matched case-control study. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/clinem/dgab518 (2021).
Muller, H. L. Bariatric interventions in craniopharyngioma patients – best choice or last option for treatment of hypothalamic obesity? J. Clin. Endocrinol. Metab. https://doi.org/10.1210/clinem/dgab567 (2021).
Bretault, M. et al. Clinical review: Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J. Clin. Endocrinol. Metab. 98, 2239–2246 (2013).
Greer, S. M., Goldstein, A. N. & Walker, M. P. The impact of sleep deprivation on food desire in the human brain. Nat. Commun. 4, 2259 (2013).
Cajochen, C., Krauchi, K. & Wirz-Justice, A. Role of melatonin in the regulation of human circadian rhythms and sleep. J. Neuroendocrinol. 15, 432–437 (2003).
Muller, H. L. et al. Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese childhood craniopharyngioma patients. J. Pediatr. Endocrinol. Metab. 19 (Suppl. 1), 423–429 (2006).
van Schaik, J. et al. Dextroamphetamine treatment for children with hypothalamic obesity. J. Endocr. Soc. 5, A62–A63 (2021).
Mason, P. W., Krawiecki, N. & Meacham, L. R. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch. Pediatr. Adolesc. Med. 156, 887–892 (2002).
Ismail, D., O’Connell, M. A. & Zacharin, M. R. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J. Pediatr. Endocrinol. Metab. 19, 129–134 (2006).
Lawson, E. A., Olszewski, P. K., Weller, A. & Blevins, J. E. The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis. J. Neuroendocrinol. 32, e12805 (2020).
Brauner, R. et al. Diazoxide in children with obesity after hypothalamic-pituitary lesions: a randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 101, 4825–4833 (2016).
Lustig, R. H. et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 88, 2586–2592 (2003).
Lustig, R. H. et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J. Pediatr. 135, 162–168 (1999).
Hamilton, J. K. et al. Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy. Int. J. Pediatr. Endocrinol. 2011, 417949 (2011).
Roth, C. L. & Reinehr, T. Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. Arch. Pediatr. Adolesc. Med. 164, 131–138 (2010).
Roth, C. L. et al. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes. Metab. 23, 363–373 (2021).
van Schaik, J. et al. Experiences with glucagon-like peptide-1 receptor agonist in children with acquired hypothalamic obesity. Obes. Facts 13, 361–370 (2020).
Tiosano, D., Eisentein, I., Militianu, D., Chrousos, G. P. & Hochberg, Z. 11β-Hydroxysteroid dehydrogenase activity in hypothalamic obesity. J. Clin. Endocrinol. Metab. 88, 379–384 (2003).
Fleseriu, M. et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3888–3921 (2016).
Daubenbuchel, A. M. et al. Eating behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of hypothalamic involvement. Pediatr. Obes. 14, e12527 (2019).
Daubenbuchel, A. M. et al. Oxytocin in survivors of childhood-onset craniopharyngioma. Endocrine 54, 524–531 (2016). The first report in patients with craniopharyngioma showing that oxytocin concentrations are decreased in the saliva of patients with anterior hypothalamic lesions.
Hoffmann, A. et al. First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine 56, 175–185 (2017).
Gebert, D. et al. De-masking oxytocin-deficiency in craniopharyngioma and assessing its link with affective function. Psychoneuroendocrinology 88, 61–69 (2018).
Brandi, M. L., Gebert, D., Kopczak, A., Auer, M. K. & Schilbach, L. Oxytocin release deficit and social cognition in craniopharyngioma patients. J. Neuroendocrinol. 32, e12842 (2020).
Daughters, K., Manstead, A. S. R. & Rees, D. A. Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. Endocrine 57, 166–174 (2017).
Aulinas, A. et al. Low plasma oxytocin levels and increased psychopathology in hypopituitary men with diabetes insipidus. J. Clin. Endocrinol. Metab. 104, 3181–3191 (2019).
Swaab, D. F., Purba, J. S. & Hofman, M. A. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J. Clin. Endocrinol. Metab. 80, 573–579 (1995).
Elowe-Gruau, E. et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J. Clin. Endocrinol. Metab. 98, 2376–2382 (2013). A unique single-centre comparison of different treatment strategies (gross total resection versus hypothalamus-sparing surgery plus radiotherapy) showing that hypothalamus-sparing strategies are superior in terms of long-term obesity and QOL and comparable in terms of relapse and progression rates.
Mortini, P. et al. Magnetic resonance imaging as predictor of functional outcome in craniopharyngiomas. Endocrine 51, 148–162 (2016).
Van Gompel, J. J., Nippoldt, T. B., Higgins, D. M. & Meyer, F. B. Magnetic resonance imaging-graded hypothalamic compression in surgically treated adult craniopharyngiomas determining postoperative obesity. Neurosurg. Focus. 28, E3 (2010).
Roth, C. L. et al. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity 23, 1226–1233 (2015).
Fjalldal, S. et al. Detailed assessment of hypothalamic damage in craniopharyngioma patients with obesity. Int. J. Obes. 43, 533–544 (2019).
Apra, C., Enachescu, C., Lapras, V., Raverot, G. & Jouanneau, E. Is gross total resection reasonable in adults with craniopharyngiomas with hypothalamic involvement? World Neurosurg. 129, e803–e811 (2019).
Lamiman, K. et al. A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications. Neurosurg. Focus. 41, E15 (2016).
Yano, S., Hide, T. & Shinojima, N. Surgical outcomes of endoscopic endonasal skull base surgery of craniopharyngiomas evaluated according to the degree of hypothalamic extension. World Neurosurg. 100, 288–296 (2017).
Bogusz, A. et al. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr. Connect. 8, 481–492 (2019). A prospective study that shows the benefit of posterior hypothalamus-sparing surgical strategies.
Beltran, C., Roca, M. & Merchant, T. E. On the benefits and risks of proton therapy in pediatric craniopharyngioma. Int. J. Radiat. Oncol. Biol. Phys. 82, e281–e287 (2012).
Prieto, R. et al. Craniopharyngioma adherence: a reappraisal of the evidence. Neurosurg. Rev. 43, 453–472 (2020).
Pascual, J. M. et al. The 2013 Sixto Obrador Award. A triple-axis topographical model for surgical planning of craniopharyngiomas. Part I: historical review of the topographical diagnosis and classification schemes of craniopharyngiomas [Spanish]. Neurocirugia 25, 154–169 (2014).
Pascual, J. M. et al. The 2013 Sixto Obrador Award. A triple-axis topographical model for surgical planning of craniopharyngiomas. Part II: anatomical and neuroradiological evidence to define triple-axis topography and its usefulness in predicting individual surgical risk [Spanish]. Neurocirugia 25, 211–239 (2014).
Neudorfer, C. et al. A high-resolution in vivo magnetic resonance imaging atlas of the human hypothalamic region. Sci. Data 7, 305 (2020).
Marcus, H. J. et al. Craniopharyngioma in children: trends from a third consecutive single-center cohort study. J. Neurosurg. Pediatr. https://doi.org/10.3171/2019.10.PEDS19147 (2019).
Grewal, M. R. et al. Gross total versus subtotal surgical resection in the management of craniopharyngiomas. Allergy Rhinol. 11, 2152656720964158 (2020).
Madsen, P. J. et al. Endoscopic endonasal resection versus open surgery for pediatric craniopharyngioma: comparison of outcomes and complications. J. Neurosurg. Pediatr. https://doi.org/10.3171/2019.4.PEDS18612 (2019).
Kiehna, E. N. & Merchant, T. E. Radiation therapy for pediatric craniopharyngioma. Neurosurg. Focus. 28, E10 (2010).
Sands, S. A. et al. Quality of life and behavioral follow-up study of pediatric survivors of craniopharyngioma. J. Neurosurg. 103, 302–311 (2005).
Mandrell, B. N. et al. Predictors of narcolepsy and hypersomnia due to medical disorder in pediatric craniopharyngioma. J. Neurooncol. 148, 307–316 (2020).
Eveslage, M. et al. The postoperative quality of life in children and adolescents with craniopharyngioma. Dtsch. Arztebl Int. 116, 321–328 (2019).
Bishop, A. J. et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int. J. Radiat. Oncol. Biol. Phys. 90, 354–361 (2014).
Merchant, T. E. et al. Disease control after reduced volume conformal and intensity modulated radiation therapy for childhood craniopharyngioma. Int. J. Radiat. Oncol. Biol. Phys. 85, e187–e192 (2013).
Hess, C. B. et al. An update from the Pediatric Proton Consortium Registry. Front. Oncol. 8, 165 (2018).
Jimenez, R. B. et al. Proton radiation therapy for pediatric craniopharyngioma. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2021.02.045 (2021).
Lo, A. C. et al. Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int. J. Radiat. Oncol. Biol. Phys. 88, 1011–1018 (2014).
Edmonston, D. et al. Limited surgery and conformal photon radiation therapy for pediatric craniopharyngeoma: long-term results from the RT1 protocol. Int. J. Radiat. Oncol. 111 (Suppl. 3), 84 (2021).
Young, M. et al. Radiotherapy alone for pediatric patients with craniopharyngioma. J. Neurooncol. 156, 195–204 (2022).
Kayadjanian, N., Schwartz, L., Farrar, E., Comtois, K. A. & Strong, T. V. High levels of caregiver burden in Prader-Willi syndrome. PLoS ONE 13, e0194655 (2018).
Tauber, M. et al. The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome. Pediatrics https://doi.org/10.1542/peds.2016-2976 (2017).
Burnett, L. C. et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J. Clin. Invest. 27, 293–305 (2017).
Deal, C. L. et al. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 98, E1072–E1087 (2013).
Feigerlova, E. et al. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. J. Clin. Endocrinol. Metab. 95, 4600–4608 (2010).
Lindgren, A. C. et al. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr. 87, 28–31 (1998).
Grugni, G., Sartorio, A. & Crino, A. Growth hormone therapy for Prader-Willi syndrome: challenges and solutions. Ther. Clin. Risk Manag. 12, 873–881 (2016).
Frixou, M. et al. The use of growth hormone therapy in adults with Prader-Willi syndrome: a systematic review. Clin. Endocrinol. 94, 645–655 (2021).
Sanchez-Ortiga, R., Klibanski, A. & Tritos, N. A. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin. Endocrinol. 77, 86–93 (2012).
Coupaye, M. et al. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood. J. Clin. Endocrinol. Metab. 98, E328–E335 (2013).
Tauber, M., Diene, G. & Molinas, C. Sequelae of GH treatment in children with PWS. Pediatr. Endocrinol. Rev. 14, 138–146 (2016).
Hoybye, C., Holland, A. J. & Driscoll, D. J., Clinical and Scientific Advisory Board of The International Prader-Willi Syndrome Organisation. Time for a general approval of growth hormone treatment in adults with Prader-Willi syndrome. Orphanet J. Rare Dis. 16, 69 (2021).
Noordam, C., Hoybye, C. & Eiholzer, U. Prader-Willi syndrome and hypogonadism: a review article. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22052705 (2021).
Pellikaan, K. et al. Hypogonadism in women with Prader-Willi syndrome – clinical recommendations based on a Dutch cohort study, review of the literature and an international expert panel discussion. J. Clin. Med. https://doi.org/10.3390/jcm10245781 (2021).
Pellikaan, K. et al. Thyroid function in adults with Prader-Willi syndrome; a cohort study and literature review. J. Clin. Med. https://doi.org/10.3390/jcm10173804 (2021).
Tauber, M. et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J. Rare Dis. 6, 47 (2011).
Miller, J. L. et al. Oxytocin treatment in children with Prader-Willi syndrome: a double-blind, placebo-controlled, crossover study. Am. J. Med. Genet. A 173, 1243–1250 (2017).
Kuppens, R. J., Donze, S. H. & Hokken-Koelega, A. C. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial. Clin. Endocrinol. 85, 979–987 (2016).
Einfeld, S. L. et al. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. Am. J. Med. Genet. A 164A, 2232–2239 (2014).
Hollander, E. et al. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi syndrome: a randomized controlled pilot trial. J. Psychiatr. Res. 137, 643–651 (2021).
Damen, L. et al. Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin. Clin. Endocrinol. 94, 774–785 (2021). One of the few randomized controlled trials that have been performed on interventions for hypothalamic obesity.
De Waele, K. et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur. J. Endocrinol. 159, 381–388 (2008).
Kimonis, V., Surampalli, A., Wencel, M., Gold, J. A. & Cowen, N. M. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLoS ONE 14, e0221615 (2019).
McCandless, S. E. et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 19, 1751–1761 (2017).
Tauber, M. et al. Prader-Willi syndrome: a model for understanding the ghrelin system. J. Neuroendocrinol. 31, e12728 (2019).
Allas, S. et al. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: a randomized placebo-controlled trial. PLoS ONE 13, e0190849 (2018).
Consoli, A. et al. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl. Psychiatry 9, 274 (2019).
Scheimann, A. O., Butler, M. G., Gourash, L., Cuffari, C. & Klish, W. Critical analysis of bariatric procedures in Prader-Willi syndrome. J. Pediatr. Gastroenterol. Nutr. 46, 80–83 (2008).
Alqahtani, A. R., Elahmedi, M. O., Al Qahtani, A. R., Lee, J. & Butler, M. G. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study. Surg. Obes. Relat. Dis. 12, 100–110 (2016).
Liu, S. Y., Wong, S. K., Lam, C. C. & Ng, E. K. Bariatric surgery for Prader-Willi syndrome was ineffective in producing sustainable weight loss: long term results for up to 10 years. Pediatr. Obes. 15, e12575 (2020).
Poretti, A., Grotzer, M. A., Ribi, K., Schonle, E. & Boltshauser, E. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev. Med. Child. Neurol. 46, 220–229 (2004).
Pedreira, C. C. et al. Health related quality of life and psychological outcome in patients treated for craniopharyngioma in childhood. J. Pediatr. Endocrinol. Metab. 19, 15–24 (2006).
Muller, H. L. et al. Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma. Klinische Padiatr. 215, 310–314 (2003).
Muller, H. L. et al. Functional capacity and body mass index in patients with sellar masses – cross-sectional study on 403 patients diagnosed during childhood and adolescence. Childs Nerv. Syst. 21, 539–545 (2005).
Muller, H. L. et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv. Syst. 21, 975–980 (2005).
Muller, H. L. Paediatrics: surgical strategy and quality of life in craniopharyngioma. Nat. Rev. Endocrinol. 9, 447–449 (2013).
Gillani, M., Hassan, S., Abdullah, U. H., Saeed Baqai, M. W. & Shamim, M. S. Quality of life in children treated for craniopharyngiomas. J. Pak. Med. Assoc. 70, 2072–2074 (2020).
Sterkenburg, A. S. et al. Childhood craniopharyngioma with hypothalamic obesity – no long-term weight reduction due to rehabilitation programs. Klinische Padiatr. 226, 344–350 (2014).
Wilson, K. S., Wiersma, L. D. & Rubin, D. A. Quality of life in children with Prader Willi syndrome: parent and child reports. Res. Dev. Disabil. 57, 149–157 (2016).
Mazaheri, M. M. et al. The impact of Prader-Willi syndrome on the family’s quality of life and caregiving, and the unaffected siblings’ psychosocial adjustment. J. Intellect. Disabil. Res. 57, 861–873 (2013).
Meade, C. et al. Prader-Willi syndrome in children: quality of life and caregiver burden. Acta Paediatr. 110, 1665–1670 (2021).
van Nieuwpoort, I. C., Deijen, J. B., Curfs, L. M. & Drent, M. L. The relationship between IGF-I concentration, cognitive function and quality of life in adults with Prader-Willi syndrome. Hormones Behav. 59, 444–450 (2011).
Apps, J. R. et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol. 135, 757–777 (2018).
Petralia, F. et al. Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell 183, 1962–1985.e31 (2020).
Patel, K. et al. Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma. Pediatr. Blood Cancer 68, e28753 (2021).
Andoniadou, C. L. et al. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol. 124, 259–271 (2012).
Donson, A. M. et al. Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J. Neuropathol. Exp. Neurol. 76, 779–788 (2017).
Grob, S. et al. Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma. Front. Oncol. 9, 791 (2019).
Aylwin, S. J., Bodi, I. & Beaney, R. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19, 544–546 (2016).
Liu, X. et al. Brown adipose tissue transplantation reverses obesity in Ob/Ob mice. Endocrinology 156, 2461–2469 (2015).
Huynh, K. D. et al. Weight loss, improved body composition and fat distribution by tesomet in acquired hypothalamic obesity. J. Endocr. Soc. 5, A64–A65 (2021).
Harat, M., Rudas, M., Zielinski, P., Birska, J. & Sokal, P. Nucleus accumbens stimulation in pathological obesity. Neurol. Neurochir. Pol. 50, 207–210 (2016).
Franco, R. R. et al. Assessment of safety and outcome of lateral hypothalamic deep brain stimulation for obesity in a small series of patients with Prader-Willi syndrome. JAMA Netw. Open. 1, e185275 (2018).
Talakoub, O. et al. Lateral hypothalamic activity indicates hunger and satiety states in humans. Ann. Clin. Transl. Neurol. 4, 897–901 (2017).
Muller, H. L. et al. Low concordance between surgical and radiological assessment of degree of resection and treatment-related hypothalamic damage: results of KRANIOPHARYNGEOM 2007. Pituitary 21, 371–378 (2018).
Sorva, R. & Heiskanen, O. Craniopharyngioma in Finland. A study of 123 cases. Acta Neurochir. 81, 85–89 (1986).
Olsson, D. S., Andersson, E., Bryngelsson, I. L., Nilsson, A. G. & Johannsson, G. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J. Clin. Endocrinol. Metab. 100, 467–474 (2015).
Nielsen, E. H. et al. Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults. J. Neurooncol. 104, 755–763 (2011).
Momin, A. A. et al. Descriptive epidemiology of craniopharyngiomas in the United States. Pituitary https://doi.org/10.1007/s11102-021-01127-6 (2021).
Schoenberg, B. S., Schoenberg, D. G., Christine, B. W. & Gomez, M. R. The epidemiology of primary intracranial neoplasms of childhood. A population study. Mayo Clin. Proc. 51, 51–56 (1976).
Dolecek, T. A., Propp, J. M., Stroup, N. E. & Kruchko, C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neurooncology 14 (Suppl 5), v1–v49 (2012).
McCarthy, B. J. et al. Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neurooncology 14, 1194–1200 (2012).
Kuratsu, J. & Ushio, Y. Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto Prefecture in the southern part of Japan. J. Neurosurg. 84, 946–950 (1996).
Ostrom, Q. T. et al. Alex’s lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neurooncology 16 (Suppl 10), x1–x36 (2015).
Thylefors, B., Negrel, A. D. & Pararajasegaram, R. Epidemiologic aspects of global blindness prevention. Curr. Opin. Ophthalmol. 3, 824–834 (1992).
McCabe, M. J., Alatzoglou, K. S. & Dattani, M. T. Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond. Best. Pract. Res. Clin. Endocrinol. Metab. 25, 115–124 (2011).
Cassidy, S. B., Schwartz, S., Miller, J. L. & Driscoll, D. J. Prader-Willi syndrome. Genet. Med. 14, 10–26 (2012).
Smith, A. & Hung, D. The dilemma of diagnostic testing for Prader-Willi syndrome. Transl. Pediatr. 6, 46–56 (2017).
Greenway, F. L. & Bray, G. A. Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr. Pract. 14, 697–703 (2008).
Sadatomo, T., Sakoda, K., Yamanaka, M., Kutsuna, M. & Kurisu, K. Mazindol administration improved hyperphagia after surgery for craniopharyngioma – case report. Neurol. Med. Chir. 41, 210–212 (2001).
Miller, J. L., Linville, T. D. & Dykens, E. M. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J. Pediatr. Endocrinol. Metab. 27, 23–29 (2014).
Kalina, M. A. et al. Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. J. Pediatr. Endocrinol. Metab. 28, 45–51 (2015).
Shoemaker, A. H. et al. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. Int. J. Obes. https://doi.org/10.1038/s41366-021-01043-6 (2022).
Salehi, P. et al. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr. Obes. 12, 221–228 (2017).
Hsu, E. A., Miller, J. L., Perez, F. A. & Roth, C. L. Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection. J. Clin. Endocrinol. Metab. 103, 370–375 (2018).
Geffner, M. et al. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J. Clin. Endocrinol. Metab. 89, 5435–5440 (2004).
Yuen, K. C. et al. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction. Eur. J. Endocrinol. 169, 511–519 (2013).
Heinks, K. et al. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine 59, 364–372 (2018).
Wijnen, M. et al. Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. Eur. J. Endocrinol. 178, 93–102 (2018).
Hoffmann, A. et al. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur. J. Endocrinol. 173, 389–397 (2015).
Guran, T. et al. The role of leptin, soluble leptin receptor, resistin, and insulin secretory dynamics in the pathogenesis of hypothalamic obesity in children. Eur. J. Pediatr. 168, 1043–1048 (2009).
van Santen, S. S. et al. Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. Eur. J. Endocrinol. 181, 173–183 (2019).
Boekhoff, S. et al. Cerebral infarction in childhood-onset craniopharyngioma patients: results of KRANIOPHARYNGEOM 2007. Front. Oncol. https://doi.org/10.3389/fonc.2021.698150 (2021).
Burman, P. et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J. Clin. Endocrinol. Metab. 98, 1466–1475 (2013).
H.L.M. (DKS2014.13) and B.B. (DKS2018.02) are supported by the German Childhood Cancer Foundation, Bonn, Germany. M.T. has received a research grant from Pfizer. E.A.L. received an investigator initiated grant from Tonix Pharmaceuticals.
This manuscript was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from Ferring, Lilly, Pfizer, Sandoz/Hexal, Novo Nordisk, Ipsen and Merck Serono, and has received reimbursement of travel expenses from Ipsen and lecture honoraria from Pfizer. M.T. has received reimbursement of participation fees for scientific meetings and continuing medical education events as well as lecture honoraria from Millendo, Pfizer, Novo Nordisk and Merck Serono. M.T. is on the scientific advisory board of OT4B, a pharmaceutical company developing oxytocin treatment in patients with PWS. E.A.L. is on the scientific advisory board and has a financial interest in OXT Therapeutics, a company developing oxytocin-based therapeutics for obesity and metabolic disease. E.A.L.’s interests were reviewed and are managed by MGH and Mass General Brigham (formerly known as Partners Healthcare) in accordance with their conflict of interest policies. J.Ö., B.B., J.-P.M.-B., S.P., T.E.M. and H.M.v.S declare no competing interests.
Peer review information
Nature Reviews Disease Primers thanks G. Chrousos, S. McCormack, S. Rose and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Müller, H.L., Tauber, M., Lawson, E.A. et al. Hypothalamic syndrome. Nat Rev Dis Primers 8, 24 (2022). https://doi.org/10.1038/s41572-022-00351-z